Achieve Life Sciences Inc (ACHV) 13F Filing Data & Analysis (Q2 2026)

ACHV ranks #4321 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ACHV is a top-conviction position for Propel Bio Management, LLC — at 13.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ACHV belongs to Frazier Life Sciences Management, L.P., but the position matters far more to Propel Bio Management, LLC, who has 13.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Ken Griffin has added to its ACHV position for two straight quarters, increasing it by $1.6M to reach $2.1M today.

Goldman Sachs Group Inc has trimmed its ACHV position for two straight quarters, cutting it by $2.0M while still holding $267.6K.

ACHV is up 2.8% today, and institutions have been net buyers of $410.8M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ACHV reported a net loss of $54.6M in its latest fiscal year.

• Not yet profitable — net loss of $54.6M in the latest fiscal year
• Net income declined year over year, from -$39.8M to -$54.6M
• Operating cash flow was negative, using $49.5M in cash
• Current ratio of 4.39x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.94x equity — within a conventional range